Wolf Group Capital Advisors Gilead Sciences, Inc. Transaction History

Wolf Group Capital Advisors

$234 Million
Q3 2024

A detailed history of Wolf Group Capital Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wolf Group Capital Advisors holds 42,798 shares of GILD stock, worth $3.91 Million. This represents 1.53% of its overall portfolio holdings.

Number of Shares

42,798

Previous 41,246 3.76%

Holding current value

$3.91 Million

Previous $2.83 Million 26.79%

% of portfolio

1.53%

Previous 1.14%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$66.59 - $83.99 $103,347 - $130,352	1,552 Added 3.76%	42,798 $3.59 Million
Q2 2024 Jul 30, 2024	SELL	$63.15 - $72.88 $98,008 - $113,109	-1,552 Reduced 3.63%	41,246 $2.83 Million
Q4 2023 Jan 22, 2024	SELL	$73.27 - $83.09 $1,318 - $1,495	-18 Reduced 0.04%	42,798 $3.47 Million
Q3 2023 Oct 31, 2023	BUY	$73.94 - $80.67 $1,330 - $1,452	18 Added 0.04%	42,816 $3.21 Million
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $1,620 - $2,326	26 Added 0.06%	42,798 $3.67 Million
Q2 2022 Jul 20, 2022	BUY	$57.72 - $65.01 $865 - $975	15 Added 0.04%	42,772 $2.64 Million
Q1 2022 Apr 20, 2022	SELL	$57.92 - $72.58 $4.95 Million - $6.21 Million	-85,514 Reduced 66.67%	42,757 $2.54 Million
Q4 2021 Jan 19, 2022	BUY	$64.88 - $73.64 $5.55 Million - $6.3 Million	85,514 Added 200.0%	128,271 $9.31 Million
Q4 2020 Jan 29, 2021	SELL	$56.65 - $64.55 $11,330 - $12,910	-200 Reduced 0.47%	42,757 $2.49 Million
Q3 2020 Oct 30, 2020	SELL	$62.1 - $78.08 $34,155 - $42,944	-550 Reduced 1.26%	42,957 $2.71 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $42,680 - $49,560	-590 Reduced 1.34%	43,507 $3.35 Million
Q1 2020 Apr 16, 2020	SELL	$62.63 - $80.22 $969,762 - $1.24 Million	-15,484 Reduced 25.99%	44,097 $3.3 Million
Q4 2019 Jan 29, 2020	SELL	$61.62 - $67.78 $230,951 - $254,039	-3,748 Reduced 5.92%	59,581 $3.87 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $421,067 - $464,784	-6,736 Reduced 9.61%	63,329 $4.01 Million
Q2 2019 Jul 17, 2019	SELL	$61.87 - $69.38 $75,543 - $84,712	-1,221 Reduced 1.71%	70,065 $4.73 Million
Q1 2019 Apr 22, 2019	SELL	$62.53 - $70.05 $3,314 - $3,712	-53 Reduced 0.07%	71,286 $4.63 Million
Q4 2018 Jan 22, 2019	SELL	$60.54 - $79.0 $70,347 - $91,798	-1,162 Reduced 1.6%	71,339 $4.46 Million
Q3 2018 Oct 23, 2018	SELL	$71.28 - $78.92 $212,556 - $235,339	-2,982 Reduced 3.95%	72,501 $5.6 Million
Q2 2018 Jul 12, 2018	SELL	$64.88 - $75.68 $244,338 - $285,010	-3,766 Reduced 4.75%	75,483 $5.35 Million
Q1 2018 Apr 25, 2018	SELL	$72.84 - $88.8 $148,957 - $181,596	-2,045 Reduced 2.52%	79,249 $5.98 Million
Q4 2017 Feb 12, 2018	SELL	$71.15 - $83.52 $144,149 - $169,211	-2,026 Reduced 2.43%	81,294 $5.82 Million
Q3 2017 Oct 23, 2017	SELL	$72.11 - $85.47 $339,998 - $402,991	-4,715 Reduced 5.36%	83,320 $6.66 Million
Q2 2017 Aug 09, 2017	BUY	N/A	88,035	88,035 $6.23 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolf Group Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Wolf Group Capital Advisors with notifications on news.

Account

Wolf Group Capital Advisors Gilead Sciences, Inc. Transaction History